12:00 AM
 | 
Mar 01, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/26 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) Merriman Curhan Ford Michael King Price target Buy -5% $30.18
King raised his target to $39-$42 from $30-$33. He thinks Ampyra dalfampridine to treat multiple sclerosis (MS) will have a strong U.S. launch this month and revised his model to include Ampyra's pricing of $1,059 per month, which exceeded his estimate of $800. Acorda has worldwide rights to the sustained-release formulation of 4-aminopyridine (4-AP) Elan Corp. plc (NYSE:ELN).
Amgen Inc. (NASDAQ:AMGN) Baird Christopher Raymond Price target Market outperform -1% $56.61
Raymond lowered his target to $69 from $70 after FDA designated a complete response from Amgen for Prolia denosumab as a Class 2 resubmission, with a July 25 PDUFA date. Raymond was hopeful for a Class 1 designation, which has a two-month review, but he still expects approval to treat postmenopausal osteoporosis. Prolia is a human mAb targeting receptor activator of NF-kappa B ligand (RANKL; TNFSF11).

Read the full 1045 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >